{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:41:18Z","timestamp":1783539678060,"version":"3.55.0"},"reference-count":30,"publisher":"Universa BV","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AGEB"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:p>Background: Previous history of COVID-19 infection is a natural booster of the vaccine response in the general population. The response to COVID-19 vaccines is lessened in Inflammatory Bowel Disease patients on selected class of immunosuppressive treatments.\n\nAims: The study was to assess anti-SARS-CoV-2 spike-specific IgG antibody response in Inflammatory Bowel Disease patients with a history of COVID-19 infection.\n\nPatients and methods: This single-center prospective study involved 504 Inflammatory Bowel Disease patients. Demographic data and clinical data were gathered through questionnaires and patient charts. Anti-SARS-CoV-2 spike-specific and antinucleocapsid antibody levels were measured at T1, T2 (after the 2-dose series), and T3 or T4 (booster vaccine).\n\nResults: This study included 504 Inflammatory Bowel Disease patients, and 234 completed one year follow-up with blood tests. Positive anti-nucleocapsid serology or history of COVID-19 infection was significantly associated with increased median anti- SARS-CoV-2 spike-specific IgG titers after the 2-dose series (1930 BAU\/mL vs. 521 BAU\/mL p &lt; 0.0001) and the booster vaccine (4390 BAU\/mL vs. 2160 BAU\/mL, p = 0.0156). Multivariate analysis showed that higher anti-SARS-CoV-2 spike-specific IgG levels were independently associated with anti-nucleocapsid antibodies at T2 (OR=2.23, p &lt; 0.0001) and T3 (OR=1.72, p = 0.00011). Immunosuppressive treatments did not impact the antibody response or levels in patients with a history of COVID-19 infection or positive anti-nucleocapsid serology.\n\nConclusions: In Inflammatory Bowel Disease, prior COVID-19 infection or positive anti-nucleocapsid serology leads to increased anti-SARS-CoV-2 spike-specific IgG levels after vaccination, regardless of immunosuppressive treatments. This emphasizes the significance of accounting for previous infection in vaccination approaches.<\/jats:p>","DOI":"10.51821\/87.2.12805","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T20:25:31Z","timestamp":1725395131000},"page":"263-273","source":"Crossref","is-referenced-by-count":1,"title":["SARS-CoV-2 antibody vaccine response in Inflammatory Bowel Disease patients with positive anti-nucleocapsid serology or history of COVID-19 infection"],"prefix":"10.51821","volume":"87","author":[{"given":"A","family":"Hoyois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Gulkilik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Mekkaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Dahma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Wambacq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Minsart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Rosewick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Liefferinckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Amininejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Van Gossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Cremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Vandenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Franchimont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27062","published-online":{"date-parts":[[2024,6]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area. JAMA - Journal of the American Medical Association. 2020;323(20):2052-2059. doi:10.1001\/jama.2020.6775","DOI":"10.1001\/jama.2020.6775"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293-1302. doi:10.1016\/S1473-3099(22)00320-6","DOI":"10.1016\/s1473-3099(22)00320-6"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Ungaro RC, Brenner EJ, Agrawal M, et al. Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry. Gastroenterology. 2022;162(1):316-319.e5. doi:10.1053\/j.gastro.2021.09.011","DOI":"10.1053\/j.gastro.2021.09.011"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Parekh R, Zhang X, Ungaro RC, et al. Presence of Comorbidities Associated with Severe Coronavirus Infection in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2022;67(4):1271-1277. doi:10.1007\/s10620-021- 07104-0","DOI":"10.1007\/s10620-021-07104-0"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology. 2020;159(2):481-491.e3. doi:10.1053\/j. gastro.2020.05.032","DOI":"10.1053\/j.gastro.2020.05.032"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Jones JL, Tse F, Carroll MW, et al. Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)\u2014Part 2: Inactivated Vaccines. Gastroenterology. 2021;161(2):681-700. doi:10.1053\/j.gastro.2021.04.034","DOI":"10.1053\/j.gastro.2021.04.034"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. American Journal of Gastroenterology. 2010;105(1):148-154. doi:10.1038\/ajg.2009.523","DOI":"10.1038\/ajg.2009.523"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Alexander JL, Kennedy NA, Ibraheim H, et al. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. Lancet Gastroenterol Hepatol. 2022;7(4):342-352. doi:10.1016\/S2468- 1253(22)00005-X","DOI":"10.1016\/S2468-1253(22)00005-X"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Doherty J, Morain NO, Stack R, et al. Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON]. J Crohns Colitis. Published online February 18, 2022. doi:10.1093\/ecco-jcc\/jjac029","DOI":"10.1093\/ecco-jcc\/jjab232.169"},{"key":"ref9","unstructured":"Thompson MG, Natarajan K, Irving SA, et al. Morbidity and Mortality Weekly Report Effectiveness of a Third Dose of MRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance-VISION Network, 10 States. https:\/\/papers.ssrn.com\/ sol3\/papers.cfm?abstract_id=3961378"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. The Lancet. 2021;398(10316):2093-2100. doi:10.1016\/S0140-6736(21)02249-2","DOI":"10.1016\/s0140-6736(21)02249-2"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Moreira ED, Kitchin N, Xu X, et al. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. New England Journal of Medicine. 2022;386(20):1910-1921. doi:10.1056\/nejmoa2200674","DOI":"10.1056\/NEJMoa2200674"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. The Lancet. 2021;398(10318):2258-2276. doi:10.1016\/S0140-6736(21)02717-3","DOI":"10.1016\/S0140-6736(21)02717-3"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Schell TL, Knutson KL, Saha S, et al. Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2022;28(11):1781-1786. doi:10.1093\/ibd\/izac082","DOI":"10.1093\/ibd\/izac082"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Long MD, Weaver KN, Zhang X, et al. Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology. 2022;20(8):1881-1883.e1. doi:10.1016\/j.cgh.2022.01.056","DOI":"10.1016\/j.cgh.2022.01.056"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Shiga H, Kakuta Y, An K, et al. Response to COVID-19 vaccine is reduced in patients with inflammatory bowel disease, but improved with additional dose. Journal of Gastroenterology and Hepatology (Australia). 2023;38(1):44-51. doi:10.1111\/jgh.16001","DOI":"10.1111\/jgh.16001"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Liu Z, Alexander JL, Lin KW, et al. Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine. Gastroenterology. 2023;164(2):300-303.e3. doi:10.1053\/j.gastro.2022.10.010","DOI":"10.1053\/j.gastro.2022.10.010"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Caldera F, Richard L, Almasry M, et al. Persistence of Antibodies Six Months after Three COVID-19 mRNA Vaccine Doses in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2023;29(10):1662-1666. doi:10.1093\/ibd\/izad019","DOI":"10.1093\/ibd\/izad019"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Bates TA, Mcbride SK, Leier HC, et al. Vaccination before or after SARS-CoV-2 Infection Leads to Robust Humoral Response and Antibodies That Effectively Neutralize Variants. Vol 7.; 2022. https:\/\/www.science.org","DOI":"10.1126\/sciimmunol.abn8014"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Meyer B, Drosten C, M\u00fcller MA. Serological assays for emerging coronaviruses: Challenges and pitfalls. Virus Res. 2014;194:175-183. doi:10.1016\/j.virusres.2014.03.018","DOI":"10.1016\/j.virusres.2014.03.018"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397(10269):99-111. doi:10.1016\/S0140-6736(20)32661-1","DOI":"10.1016\/S0140-6736(20)32661-1"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. New England Journal of Medicine. 2021;384(23):2187-2201. doi:10.1056\/nejmoa2101544","DOI":"10.1056\/NEJMoa2101544"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Wong SY, Wellens J, Helmus D, et al. Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium. Inflamm Bowel Dis. 2023;29(11):1693-1705. doi:10.1093\/ibd\/izad097","DOI":"10.1093\/ibd\/izad230"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Leclercq V, Van den Houte N, Gisle L, et al. Prevalence of Anti-SARS-CoV-2 Antibodies and Potential Determinants among the Belgian Adult Population: Baseline Results of a Prospective Cohort Study. Viruses. 2022;14(5). doi:10.3390\/v14050920","DOI":"10.3390\/v14050920"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Caron B, Neuville E, Peyrin-Biroulet L. Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients\u2019 Survey. Dig Dis Sci. 2022;67(6):2067- 2073. doi:10.1007\/s10620-021-07040-z","DOI":"10.1007\/s10620-021-07040-z"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Clarke K, Pelton M, Stuart A, et al. COVID-19 Vaccine Hesitancy in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2022;67(10):4671-4677. doi:10.1007\/s10620-021-07377-5","DOI":"10.1007\/s10620-021-07377-5"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Doherty J, O\u2019Morain N, Stack R, et al. Reduced Serological Response to COVID-19 Booster Vaccine is Associated with Reduced B Cell Memory in Patients With Inflammatory Bowel Disease; VARIATION [VAriability in Response in IBD AgainsT SARS-COV-2 ImmunisatiON]. J Crohns Colitis. 2023;17(9):1445-1456. doi:10.1093\/ecco-jcc\/jjad065","DOI":"10.1093\/ecco-jcc\/jjad065"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Gonz\u00e1lez Cueto E, Edmans M, Wellens J, et al. Antibody, not Cellular, Immune Responses to SARS-CoV-2 Vaccination Outperform Infection in Inflammatory Bowel Disease Patients. Inflamm Bowel Dis. Published online November 3, 2023. doi:10.1093\/ibd\/izad265","DOI":"10.1093\/ibd\/izad265"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Epsi NJ, Richard SA, Lindholm DA, et al. Understanding \u201cHybrid Immunity\u201d: Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines. Clinical Infectious Diseases. 2023;76(3):E439-E449. doi:10.1093\/cid\/ciac392","DOI":"10.1093\/cid\/ciac392"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Zuo F, Abolhassani H, Du L, et al. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nat Commun. 2022;13(1). doi:10.1038\/s41467-022-30340-5","DOI":"10.1038\/s41467-022-30340-5"}],"container-title":["Acta Gastro Enterologica Belgica"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T20:34:27Z","timestamp":1725395667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ageb.be\/ageb-journal\/ageb-volume\/ageb-article\/2162\/SARS-CoV-2%20antibody%20vaccine%20response%20in%20Inflammatory%20Bowel%20Disease%20patientswith%20positive%20anti-nucleocapsid%20serology%20or%20history%20of%20COVID-19%20infection\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,6]]},"published-print":{"date-parts":[[2024,6]]}},"URL":"https:\/\/doi.org\/10.51821\/87.2.12805","relation":{},"ISSN":["1784-3227"],"issn-type":[{"value":"1784-3227","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}